While immune checkpoint inhibitors (ICIs) targeting programmed cell death ligand 1 (PD-1) or cytotoxic T lymphocyte-associated protein-4 (CTLA-4) have achieved tumor regression in several cancers [1,2], the unexpected low response rate, typically below 30%, hinders the full display of this revolutionary procedure [3]. This evidence concerns the gene CTLA4 and neoplasm.